Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06211036 |
Title | Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305) |
Acronym | DeLLphi-305 |
Recruitment | Recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | No |
Sponsors | Amgen |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | TUR | CHE | BRA | AUS | ARG |